cediranib + durvalumab

Cediranib + durvalumab is an investigational combination therapy consisting of two agents: cediranib, a small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), and durvalumab, a monoclonal antibody that blocks programmed death-ligand 1 (PD-L1). Cediranib inhibits angiogenesis by blocking VEGF-mediated signaling pathways essential for tumor blood vessel formation. Durvalumab enhances anti-tumor immune responses by preventing PD-L1 from binding to its receptors PD-1 and CD80 on T cells, thereby promoting cytotoxic T cell activity against tumor cells. This combination is being studied primarily in recurrent or resistant gynecologic cancers such as ovarian and endometrial cancer[1][2][3][4][5][7].

Brand names

none

Other names

durvalumab + cediranibMEDI4736 + AZD2171